Blue Earth Therapeutics is highlighting results from a preclinical study evaluating the efficacy of actinium-225 (Ac-225) rhPSMA-10.1 compared with lutetium (Lu-177) rhPSMA-10.1 for the treatment of prostate cancer.
The results were presented at the European Association of Nuclear Medicine (EANM23) in Vienna and showed that both Ac-225 rhPSMA-10.1 and Lu-177 rhPSMA-10.1 offered excellent prostate-specific membrane antigen binding, high cellular internalization, and similar lipophilicity, the company said.
